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Abstract
Background: Previous evaluations of oncological medicines in the German early benefit assessment (EBA)
procedure have demonstrated inconsistent acceptance of endpoints by regulatory authorities and the Federal Joint
Committee (G-BA). Accepted standard endpoints for regulatory purposes are frequently not considered as patient-
relevant in the German EBA system.
In this study the acceptance of clinically acknowledged primary endpoints (PEPs) from regulatory trials in EBAs
conducted by the G-BA was evaluated across three therapeutic areas.
Methods: Medicines for oncological, metabolic and infectious diseases with EBAs finalised before 25 January 2016
were evaluated. Respective manufacturer’s dossiers, regulatory assessments, G-BA appraisals and oral hearing
minutes were reviewed, and PEPs were examined to determine whether they were considered relevant to patients
by the G-BA. Furthermore, the acceptance of symptomatic vs asymptomatic PEPs was also analysed.
Results: A total of 65 EBAs were evaluated. Mortality PEPs were widely accepted as patient-relevant but were only
used in a minority of EBAs and exclusively in oncological diseases. Morbidity PEPs constituted around 72 % of
assessed PEPs, but were excluded from the EBA in over half of the corresponding assessments as they were not
considered patient-relevant. Symptomatic endpoints were largely deemed patient-relevant, whereas acceptance of
asymptomatic endpoints varied between therapeutic areas.
Conclusions: This evaluation identified inconsistencies in patient relevance of morbidity-related PEPs as well as in
acceptance of asymptomatic endpoints by the G-BA in all three disease areas examined. Better harmonisation
between the regulatory authorities and the G-BA is still required after 5 years of AMNOG health technology
assessment in Germany.
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Background
Since 2011, all new medicines in Germany are required
to undergo an early benefit assessment (EBA) in
comparison to a pre-specified appropriate comparator
[1]. At market entry, the pharmaceutical manufacturer
(PM) needs to submit an EBA dossier evaluating the
additional benefit of the drug, based on available clinical
trial data, to the Federal Joint Committee (Gemeinsamer
Bundesausschuss, G-BA).
The extent of additional benefit is classified by the G-BA
as major (1), considerable (2), minor (3), non-quantifiable
(4), no additional benefit (5), and less benefit (6) [2]. The
benefit rating serves as the main basis for subsequent price
negotiations for reimbursement between the PM and statu-
tory health insurance providers.
For the determination of additional benefit the G-BA
requests efficacy data in three different categories:
mortality, morbidity and health-related quality of life
(HRQoL) [2, 3]. However, the G-BA only takes into
account endpoints deemed to be patient-relevant.
Importantly, the opinion of the G-BA on patient rele-
vance of endpoints frequently diverges from those of
regulatory authorities [4–8].
A previous analysis of endpoints in oncology indicated
acceptance by the G-BA of endpoints related to mortal-
ity, while morbidity endpoints were largely disregarded
[4]. The current analysis extends the scope beyond on-
cology to evaluate if the identified trends also apply to
other disease areas. Benefit assessments in the three
most frequently assessed therapeutic areas (with ≥10
finalised and evaluable assessments) were analysed:
oncological, metabolic, and infectious diseases. For all
primary endpoints (PEPs), patient relevance was evalu-
ated and used to determine whether these PEPs would
be taken into consideration in an EBA by the G-BA.
Methods
Analysis set: EBA dossiers submitted by the PMs, the cor-
responding G-BA appraisals, and oral hearing minutes, all
obtained from the G-BA website, were used as sources of
data [9]. Dossiers were not included in the analysis if the
G-BA’s view on patient relevance of endpoints was not
discernible. This could be due to i) no dossier being sub-
mitted by the PM, ii) inability to evaluate acceptance of
PEP by the G-BA (due to use of inappropriate comparator,
inadequate indirect comparison, or dossiers/studies being
incomplete), or iii) if a more recent assessment for the
same medicine and indication was available.
Analysis of patient relevance of primary endpoints in
the benefit assessment by the G-BA: The resulting dataset
was used to analyse whether PEPs used in the clinical
studies and reported in the PM dossiers went on to be
accepted as patient-relevant in the G-BA appraisals.
PEPs were recorded as:
 patient-relevant when this was explicitly mentioned
in the G-BA appraisal, or the corresponding data
were used to justify an additional benefit,
 partially patient-relevant when the PEP was a
composite or co-primary endpoint with both
patient-relevant and non-patient-relevant compo-
nents, or
 not relevant to patients when the G-BA clearly
questioned the validity of the endpoint or the appraisal
did not mention the PEP data or contained no clear
statement of its inclusion.
Following determination of the G-BA’s view on patient
relevance of each PEP, they were categorised as either
symptomatic or asymptomatic. To ensure this categor-
isation of the endpoints was unbiased and meaningful,
we utilised multiple sources of information integral to
the EBA process to inform this procedure. Specifically,
the categorisations were based on definitions and
descriptions of the endpoints and the respective
discussions within the dossiers, the assessments by the In-
stitute for Quality and Efficiency in Healthcare (Institut
für Qualität und Wirtschaftlichkeit im Gesundheitswesen,
IQWiG), and the G-BA appraisals. The oral hearing at the
G-BA aims to provide clarification on critical and contro-
versial topics. Key representatives of the relevant medical
and scientific societies are always attending those hearings.
Thus, the oral hearing minutes served as a source of expert
opinion which we referred to for categorisation of certain
endpoints along with supporting scientific statements.
The medicines were divided into therapeutic areas, as
categorised by the G-BA, and only therapeutic areas
with ≥10 finalised and evaluable EBAs as of 25 January
2016 were considered, which led to the inclusion of




Inclusion of therapeutic areas with ≥10 finalised and
evaluable EBAs (oncological, metabolic, and infectious
disease areas) resulted in 97 EBAs which were consid-
ered for evaluation. Of these, 65 (67 %) were evaluable
according to the inclusion criteria. Table 1 summarises
the number of EBAs included in the analysis and the
main reasons for exclusion of EBAs from the analysis set
by therapeutic area.
A high proportion of EBAs in metabolic diseases (19
of 34, 56 %) were not evaluable, mainly because the G-
BA objected to the methodological execution of the
studies for reasons including use of inappropriate com-
parator or indirect comparison, and incomplete dossiers
or studies. A list of EBAs and the respective PEPs evalu-
ated in the analysis is presented in Table 2.
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Analysis of patient relevance of primary endpoints in the
benefit assessment by G-BA
All therapeutic areas
This analysis set consisted of 65 PEPs obtained from 65
EBA dossiers. The G-BA deemed the PEPs as relevant to
patients in 31 (48 %) of 65 EBAs, not relevant to patients
in 25 (38 %), and partially patient-relevant in nine (14 %)
assessments (refer to sections on individual therapeutic
areas for more details on specific PEPs).
Analysis by endpoint category showed that the major-
ity of PEPs were morbidity endpoints (47 of 65, 72 %).
Mortality PEPs were used in 11 of 65 PM submissions
(17 %), all of which concerned oncological diseases and
were deemed patient-relevant by the G-BA (Fig. 1a).
Morbidity PEPs were considered patient-relevant in 20
of 47 (43 %) EBAs and partially patient-relevant in two
cases (4 %). In seven EBAs the PEP was a composite
endpoint of mortality and morbidity and in each case
deemed partially patient-relevant. Six of these cases were
in oncological diseases and one was in the metabolic dis-
ease area (see also sections on individual therapeutic
areas). No assessment included HRQoL as a PEP.
Oncological diseases
In oncological diseases 36 of 47 PM submissions were
analysed (Table 1). Mortality PEPs were reported in 11
of the 36 EBAs (all overall survival [OS]) and regarded
as patient-relevant in the benefit assessment by the G-
BA in all cases (Fig. 1b). Fifteen of 19 (79 %) morbidity
PEPs (mostly progression-free survival [PFS]) were
deemed not patient-relevant. The three patient-relevant
morbidity PEPs were major cytogenic response (MCR)
(bosutinib, chronic myeloid leukaemia), reduction of
spleen volume by >35 % (ruxolitinib, chronic myeloprolif-
erative diseases), and haematocrit control without
phlebotomy and reduction of spleen volume by >35 %
(ruxolitinib, polycythaemia vera). For one composite mor-
bidity endpoint, namely partial and complete durable
tumour and symptomatic response, only complete re-
sponse was considered patient-relevant and included in
the G-BA appraisal (siltuximab, multicentric Castleman’s
disease). Six assessments had co-primary endpoints,
comprising mortality and morbidity (all OS and PFS). In
all these cases only OS was considered in the appraisal.
Metabolic diseases
In metabolic diseases, 34 PM submissions were available,
15 of which were analysed (Table 1). All PEPs were mor-
bidity endpoints, apart from one composite mortality/
morbidity PEP (Fig. 1c) and three morbidity PEPs were
deemed patient-relevant in the benefit assessments. One
of these PEPs was glycated haemoglobin (HbA1c) in type
1 diabetes (insulin degludec), which was explicitly
specified by the G-BA as a validated and patient-relevant
endpoint. The others were 6-minute walk test (6MWT)
in type IVA mucopolysaccharidose (elosulfase alfa), and
median urinary free cortisol level (mUFC) in pituitary
gland dysfunction (pasireotide).
In the ten EBAs where PEPs were not considered
patient-relevant by the G-BA, PEPs were HbA1c and
FEV1 (forced expiratory volume in 1 second) in type 2
diabetes and cystic fibrosis, respectively. In eight benefit
assessments (albiglutide, dulaglutide, linagliptin [re-assess-
ment], saxagliptin, saxagliptin/metformin, sitagliptin, sita-
gliptin/metformin, vildagliptin [re-assessment]) the PEP
HbA1c was not explicitly mentioned as patient-relevant
and not considered in the G-BA benefit evaluation, and
therefore assumed to be not relevant to patients according
to the evaluation criteria of this analysis stated above. In
the two assessments of ivacaftor, FEV1 data was not taken
into consideration by the G-BA as there were different
opinions within the G-BA regarding its patient relevance.
In two EBAs the PEP was only partially accepted as
patient-relevant by the G-BA. For eliglustat (Gaucher
disease type 1) the PEP was a co-primary endpoint, con-
sisting of two endpoints. The first was the composite
morbidity endpoint stable health status (spleen volume,
liver volume, haemoglobin and thrombocyte count) and
the second percentage change in spleen volume, where
only the change in spleen volume was deemed patient-
relevant. For pasireotid (acromegaly) the PEP was bio-
chemical control (defined as a combination of reduction
of the mean growth hormone [GH] level below 2.5 μg/l
and normalisation of the age- and sex-adjusted insulin-
Table 1 Inclusion vs exclusion of EBAs by therapeutic area
Therapeutic area EBAs (n) Assessments in analysis set (n) Main reason for EBAs not being evaluablea
Included Excluded No dossier
submitted
Data on PEP acceptance
by G-BA not evaluable
Newer assessment available
(same medicine and indication)
Oncological diseases 47 36 11 2 6 3
Metabolic diseases 34 15 19 3 14 2
Infectious diseases 16 14 2 0 2 0
Total 97 65 32 5 22 5
aEBAs were excluded from the analysis when no dossier was submitted by the PM, a newer assessment was available (same medicine and indication) or the G-BA’s viewpoint
on the patient relevance of the PEP could not be discerned (due to incomplete dossiers or studies, use of inappropriate comparators, or inadequate indirect comparisons)
EBA Early benefit assessment, G-BA Federal Joint Committee, n Number of EBAs, PEP Primary endpoint, PM Pharmaceutical manufacturer
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Table 2 EBAs included in the analysis set and respective primary endpoints
Medicine Indication Primary endpoint (PEP) Therapeutic expert panel present
at oral hearing
Oncological diseases
Abiraterone acetate Prostate carcinoma OS BDU, DGHO, DVPZ
Abiraterone acetatea Prostate carcinoma OS, rPFS DGHO
Afatinibc Non-small cell lung cancer PFS DGHO, DKG (Working Group on
Thoracic Oncology of the AIO)
Aflibercept Metastatic colorectal cancer OS DGVS
Axitinib Renal cell carcinoma PFS DGHO





Cabazitaxel Prostate carcinoma OS DGHO, DKG
Cabozantinib Thyroid gland neoplasia PFS DGE (thyroid gland section),
DGHO, DGN
Crizotinib Non-small cell lung cancer PFS, ORR DGHO, POA, representatives from
leading oncology centres
Decitabine Myeloid leukaemia OS DGHO
Enzalutamide Prostate carcinoma OS DGHO, DGU
Enzalutamidea Prostate carcinoma OS, rPFS DGHO
Eribulin Breast cancer OS DGHO






Idelalisib Chronic lymphocytic leukaemia,
follicular lymphoma
PFS DGHO, GLSG, representative from
the University Hospital Gießen
Ipilimumab Melanoma OS DGHO
Lenvatinib Thyroid gland neoplasia PFS DGHO
Nintedanib Non-small cell lung cancer PFS DGHO, DKG (Working Group on
Thoracic Oncology of the AIO),
representative from the LungenClinic
Grosshansdorf
Nivolumab Melanoma OS, PFS ADO, DGHO
Obinutuzumab Chronic lymphocytic leukaemia PFS DGHO
Olaparib Ovarian cancer PFS DGHO
Pertuzumab Breast cancer PFS, ORR AGO, DGHO
Pomalidomide Multiple myeloma PFS DGHO, representatives from the
University Hospitals of Heidelberg,
Tübingen and Würzburg
Radium-223-dichloride Prostate carcinoma OS DGHO
Ramucirumab Stomach cancer OS DGHO, DGVS







Ruxolitiniba Polycythaemia vera Haematocrit control without
phlebotomy and ≥35 %
reduction in spleen volume
DGHO
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Table 2 EBAs included in the analysis set and respective primary endpoints (Continued)





Sipuleucel-T Prostate carcinoma OS DGHO, representative from the
University Hospital Tübingen,
Department of Urology
Trastuzumab emtansine Breast cancer OS, PFS AGO, DGHO
Vandetanibb Thyroid gland neoplasia PFS DGHO
Vemurafenibc Melanoma OS, PFS ADO, DGHO
Vismodegib Basal cell cancer ORR DGHO, DGMKG, German Society
of Dermatology
Metabolic diseases
Albiglutide Diabetes mellitus type 2 HbA1c DDG, Diabetes Research Group HZM,
representative from the University
Hospital Carl Gustav Carus (Dresden)
Dulaglutide Diabetes mellitus type 2 HbA1c BVND, DDG, Diabetes Research
Group HZM
Eliglustat Gaucher disease type 1 Stable health status (decrease
in spleen and liver volume,
Hb, thrombocytes) and
%-change in spleen volume
ASIM, DGVS, representative from
the Charité University Medicine
Berlin
Elosulfase alfa Mucopolysaccharidose type IVA
(Morquio A syndrome)
6MWT ZSE Wiesbaden
Insulin degludeca Diabetes mellitus type 1 HbA1c DDG
Ivacaftor Cystic fibrosis FEV1% -
Ivacaftora Cystic fibrosis FEV1% -
Linagliptinb Diabetes mellitus type 2 HbA1c BVND, DDG, Diabetes Research
Group HZM
Pasireotide Pituitary gland dysfunction mUFC≤ ULN -
Pasireotidea Acromegaly Biochemical control -
Saxagliptin Diabetes mellitus type 2 HbA1c DDG, Working Group on
Pharmacoepidemiology, Diabetes
Research Group HZM, Diabetes
Centre Bad Lauterberg
Saxagliptin/metformin Diabetes mellitus type 2 HbA1c BVND
Sitagliptin Diabetes mellitus type 2 HbA1c DDG, Working Group on
Pharmacoepidemiology, Diabetes
Research Group HZM, Diabetes
Centre Bad Lauterberg
Sitagliptin/metformin Diabetes mellitus type 2 HbA1c DDG, Diabetes Centre Bad Lauterberg,
Diabetes Research Group HZM,
Working Group on
Pharmacoepidemiology
Vildagliptinb Diabetes mellitus type 2 HbA1c BVND, DDG
Infectious diseases
Boceprevir Chronic hepatitis C SVR bng, DGVS, German Liver Foundation
Daclatasvir Chronic hepatitis C SVR bng, dagnä, DGIM, DGVS
Dasabuvir Chronic hepatitis C SVR bng, dagnä, DGIM, DGVS
Dolutegravir HIV infection VR dagnä, DAIG
Dolutegravir/abacavir/lamivudine HIV infection VR -
Elvitegravir/cobicistat/emtricitabin/
tenofovir-disoproxil
HIV infection VR dagnä, DAIG
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like growth factor 1 [IGF-1] level after 24 weeks). The
PM defined biochemical control as a composite mortality/
morbidity endpoint. However the G-BA did not accept
the mortality component due to lack of validation.
Infectious diseases
In infectious diseases 14 of 16 PM submissions were in-
cluded in the analysis set (Table 1). There were no mor-
tality PEPs in infectious diseases. All 14 PEPs concerned
morbidity (Fig. 1d), and all were accepted as patient-
relevant by the G-BA. In most cases (13 of 14) the PEP
was viral response (sustained viral response [SVR] in
hepatitis C or viral response [VR] in HIV-infected pa-
tients), and in one case, the PEP was overall cure (fidax-
omicin, clostridium infection).
Acceptance of symptomatic vs asymptomatic PEPs
PEPs were categorised as symptomatic or asymptomatic
according to the definition of the PEP and based on the
appraisal documents as well as scientific discussions dur-
ing the hearing process. A list of therapeutic area expert
panels attending the oral hearings is shown in Table 2.
Table 3 summarises each evaluated PEP and the results
of the categorisation by therapeutic area (see Additional
file 1: Table S1 for a table listing the rationale of
categorisation for each endpoint).
Asymptomatic PEPs mostly comprised laboratory
parameters (e.g. HbA1c in diabetes) or endpoints
involving imaging outcomes (e.g. PFS or objective
response rate [ORR]) [9]. Symptomatic endpoints in-
cluded outcomes directly experienced by the patient, for
example OS in oncological conditions and 6MWT in
mucopolysaccharidose [9]. For other PEPs (complete/par-
tial durable tumour and symptomatic response, overall
cure), symptomaticity was self-explanatory by their defini-
tions [9]. Regarding the symptomaticity of the PEPs re-
lated to reduction in spleen or liver volume, an
independent Gaucher disease type 1 expert (a member of
the German Working Group for Congenital Metabolic
Disorders in Internal Medicine [Arbeitsgemeinschaft für
angeborene Stoffwechselstörungen in der Inneren Medizin,
ASIM]) stated in the minutes of the oral hearing proced-
ure for eliglustat that the spleen volume in patients prior
to treatment is typically increased 15-fold to ca. 2 L [9].
Since the measured reduction with eliglustat treatment
was around 30 % and therefore easily palpable we assigned
the reduction in spleen volume as a symptomatic end-
point. A similar reasoning applies to the reduction of
≥35 % of spleen volume in the EBA of ruxolitinib in the
indications chronic myeloproliferative diseases and poly-
cythaemia vera. In contrast, a closer analysis of the data
for Gaucher disease showed that the relative enlargement
and reduction in liver volume before and after eliglustat
treatment were too small to be palpable and thus deemed
not symptomatic.
Subsequently, we compared the consideration of
symptomatic vs asymptomatic PEPs by the G-BA in
evaluating additional benefit. For three PEPs the oral
hearing minutes were consulted in order to categorise
them as symptomatic or asymptomatic, as described
above. Symptomatic endpoints were mostly regarded as
patient-relevant (Table 3 A), apart from partial durable
tumour and symptomatic response (siltuximab, multi-
centric Castleman’s disease) (Table 3 B). Asymptomatic
Table 2 EBAs included in the analysis set and respective primary endpoints (Continued)
Emtricitabine/rilpivirine/
tenofovirdisoproxil
HIV infection VR dagnä, DAIG
Fidaxomicin Clostridium infection Overall cure DGHO, DGVS
Ledipasvir/sofosbuvir Chronic hepatitis C SVR bng, dagnä, DGIM, DGVS
Ombitasvir/paritaprevir/ritonavir Chronic hepatitis C SVR bng, dagnä, DGIM, DGVS
Rilpivirine HIV infection VR DAIG, dagnä
Simeprevir Chronic hepatitis C SVR bng, dagnä, DGI, DGIM, DGVS
Sofosbuvir Chronic hepatitis C SVR bng, dagnä, DGIM
Telaprevir Hepatitis C SVR bng, DGVS, German Liver
Foundation
aNew therapeutic indication, bRe-assessment for the same indication, cRe-assessment after expiration of G-BA appraisal, dRuxolitinib is an orphan drug, but has
undergone a regular EBA process after having reached sales of >€50 million per year
6MWT 6-minute walking test, ADO Working Group on Dermatological Oncology, AGO Working Group on Gynaecologic Oncology, AIO Working Group on Internal
Oncology, ASIM Working Group on Congenital Metabolic Disorders in Internal Medicine, BDU Professional Association of German Urologists, bng Federal Association of
Registered Gastroenterologists, BVND Federal Association of Registered Diabetologists, dagnä German Working Group of Registered Doctors in the Care of HIV-infected Persons,
DAIG German AIDS Society, DDG German Diabetes Society, DGE German Society of Endocrinology, DGHO German Society of Hematology and Medical Oncology, DGI German
Society of Infectious Diseases, DGIM German Society of Internal Medicine, DGMKG German Society of Oral and Maxillofacial Surgery, DGN German Society of Nuclear Medicine,
DGU German Society of Urology, DGVS German Society of Gastroenterology, Digestive and Metabolic Diseases, DKG German Cancer Society, DVPZ Umbrella Organisation of
Prostate Centres in Germany, EBA Early benefit assessment, FEV1 Forced expiratory volume in 1 second, GLSG German Low Grade Lymphoma Study Group, Hb Haemoglobin,
HbA1c Glycated haemoglobin, HIV Human immunodeficiency virus, HZM Helmholtz Centre Munich, POAWorking Group on Pulmonary Oncology, MCRMajor cytogenic
response,mUFCMedian urinary free cortisol, ORR Objective response rate, OS Overall survival, PFS Progression-free survival, rPFS Radiographic progression-free survival,
SVR Sustained viral response, ULN Upper limit of normal, VR Viral response, ZSE Centre for Rare Diseases
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endpoints (mainly laboratory parameters and endpoints
assessed by imaging techniques) were largely deemed
not relevant to patients. This had considerable impact
on benefit assessment of oncology medications, since
PFS and ORR are widely used PEPs which are generally
accepted as patient-relevant by the European Medicines
Agency (EMA), but were not deemed patient-relevant by
the G-BA (Table 3 B). In metabolic diseases HbA1c was
only considered patient-relevant in type 1 diabetes. In
contrast, asymptomatic viral response endpoints (VR and
SVR) in infectious diseases (mainly hepatitis C and HIV
infection) were readily accepted as patient-relevant by the
G-BA.
Discussion
This analysis demonstrates that specific morbidity PEPs
from the EBA are categorically excluded by the G-BA
across major disease areas, irrespective of indication and
disease stage. Typically, these are PEPs used in pivotal
studies for marketing authorisation. The respective clinical
studies were specifically designed to show clinical benefit
based on these endpoints. The aim of the EBA is to assess
the additional benefit of a new medicine compared to the
prespecified comparative treatment. This generally differs
from the aim of regulatory authorities, which is to evaluate
the benefit vs risk profile of a new medicine. Nevertheless,
the methods and standards of evidence-based medicine
Fig. 1 Patient relevance of PEPs according to the G-BA by endpoint dimension. a All three therapeutic areas, b oncological diseases, c metabolic
diseases, and d infectious diseases. HRQoL was not used as PEP for any assessment, therefore it is not shown in the graphs
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apply to both evaluation procedures. Furthermore, primary
endpoints of pivotal studies which led to EMA approval of
the investigated drug should be accepted as patient-relevant,
irrespective of whether ‘benefit’ or ‘additional benefit’ is
under consideration. To suggest that these primary study
endpoints are not relevant to patients, as the G-BA does,
creates a major dilemma in clinical development and impli-
citly questions the ethical conduct of studies.
Our analysis by outcome dimension showed a strong
dominance of morbidity over mortality PEPs (47 vs 11).
While the mortality PEPs were accepted as patient-
relevant without exception, less than half of the morbidity
PEPs were deemed patient-relevant. Interestingly, the
acceptance varied by therapeutic area, revealing a disad-
vantage for oncological and metabolic disease indications,
where morbidity PEPs were predominantly regarded as
not patient-relevant. Considering that the majority of
these PEPs were accepted by regulatory authorities for
marketing authorisation, the classification of such a large
proportion of PEPs as not relevant to patients by the G-
BA highlights marked differences in data interpretation by
regulatory and health technology assessment (HTA)
bodies. A similar finding was also demonstrated in a com-
parative analysis of parallel scientific advice of different
European HTA bodies and the EMA [10].
The PEPs that were most frequently dismissed as not
patient-relevant were PFS in oncological diseases and
HbA1c in metabolic diseases (except for type 1 diabetes).
Despite opposing views on patient relevance of PFS within
the G-BA (e.g. afatinib, axitinib, crizotinib, eribuline) [9]
data on this endpoint were systematically excluded from
benefit assessments, based on the justification that PFS
evaluation utilises asymptomatic endpoint assessment
techniques such as imaging. Conversely, in infectious dis-
eases, the PEP SVR was accepted as patient-relevant in
hepatitis C despite being an asymptomatic surrogate
endpoint lacking formal validation. PEPs in neurological
diseases were also evaluated but ultimately excluded from
the analysis set as only six assessments were evaluable.
Here, morbidity PEPs were largely accepted as patient-
relevant by the G-BA (5 of 6 EBAs).
The results of our analysis clearly demonstrate incon-
sistency in the G-BA’s approach to judging the patient
relevance of PEPs between disease areas. For example, in
infectious diseases, the G-BA has shown some flexibility
in accepting the asymptomatic endpoint SVR as patient-
relevant. On the other hand, in oncological and meta-
bolic diseases some asymptomatic endpoints (PFS in
cancers and HbA1c in type 2 diabetes) are categorically
dismissed, without taking into consideration the differ-
ent disease profiles of the indications. This is in contrast
to the EMA, which adopts a broader approach when
evaluating patient relevance and takes indication,
difficulty in obtaining mortality data, and priority of ac-
celerating patient access into account.
We welcome the flexibility the G-BA has shown regarding
the acceptance of SVR as patient-relevant in hepatitis C, but
identify a need to expand this flexibility to other endpoints.
The general dismissal of PFS is questionable since in some
cancers, such as ovarian cancer, it has been suggested that
improved PFS is associated with clinical benefit and is a
valid surrogate for extended OS [11]. Nevertheless the G-
Table 3 G-BA acceptance of symptomatic vs asymptomatic morbidity PEPs as (A) patient-relevant and (B) non-patient-relevant
Oncological diseases Metabolic diseases Infectious diseases
(A) Morbidity PEPs accepted as patient-relevant by the G-BA
Symptomatic Complete durable tumour & symptomatic responsea 6MWT Overall cure
≥35 % reduction in spleen volumea Reduction in spleen volumea -
Asymptomatic Haematocrit control without phlebotomya HbA1c (Type 1 diabetes) Viral response
(VR, SVR)
MCR mUFC -
- Biochemical control (mean GH <2.5 μg/L
and normalisation of IGF-1)
-
(B) Morbidity PEPs not accepted as patient-relevant by the G-BA
Symptomatic Partial durable tumour & symptomatic responsea - -
Asymptomatic PFSa HbA1c (Type 2 diabetes) -
ORR Haemoglobin levela -
- Thrombocyte counta -
- Reduction in liver volumea -
- FEV1 -
aThis PEP was a component of a co-primary endpoint in at least one dossier
6MWT 6-minute walking test, FEV1 Forced expiratory volume in 1 second, G-BA Federal Joint Committee, GH Growth hormone, HbA1c Glycated haemoglobin, IGF-1
Insulin-like growth factor 1, MCR Major cytogenic response, mUFC Median urinary free cortisol, ORR Objective response rate, OS Overall survival, PEP Primary
endpoint, PFS Progression-free survival, SVR Sustained viral response, VR Viral response
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BA did not accept PFS as patient-relevant in the EBA of ola-
parib for the treatment of ovarian cancer [9].
The success of novel anticancer drugs in recent years
has led to a classification shift of various oncological
conditions from acutely fatal to chronic disease. Similar to
chronic diseases such as diabetes, it is challenging to ob-
tain mortality data showing significant differences in those
oncological diseases with slow progression and low death
rates. For these reasons, PFS has gained importance as a
PEP in clinical trials because it is an early detectable and
meaningful endpoint for disease progression [12, 13].
Similarly to PFS, HbA1c is routinely used as a surro-
gate endpoint in diabetes mellitus and widely accepted
by regulatory authorities [14]. For example the EMA
states in its “Note for guidance on clinical investigation
of medicinal products in the treatment of diabetes melli-
tus” that HbA1c is the most widely accepted measure of
overall, long-term blood glucose control in type 1 and
type 2 diabetes, and therefore an appropriate primary
study endpoint [15]. Moreover, this guidance states that
reduction of HbA1c is directly related to a reduced risk
of developing vascular complications. The G-BA, how-
ever, only accepts HbA1c as a patient-relevant endpoint
in type 1 diabetes, but not in type 2.
For the patient relevance of morbidity endpoints, clarifica-
tion of its definition and determination criteria by the G-BA
are urgently needed, particularly in oncological diseases and
type 2 diabetes, as currently no clear criteria for patient
relevance are listed in the G-BA rules of procedure
[2]. Representatives from patient advocacy groups and
other external experts are consulted at several stages
of the assessment procedure, potentially also concern-
ing the patient relevance of endpoints, but their influ-
ence on the benefit appraisal is not transparent and
has been criticised as insufficient [16, 17]. In a recent press
release from the German Society for Hematology and
Medical Oncology (Deutsche Gesellschaft für Hämatologie
und Medizinische Onkologie, DGHO) a DGHO board mem-
ber criticised the fact that market authorisation, EBA, and
treatment guidelines often come to different conclusions,
despite being based on the same clinical data, making it dif-
ficult for doctors to make treatment decisions [18].
Alignment of study requirements between the G-BA
and regulatory authorities is necessary in order to opti-
mise trial design and reduce patient sample sizes, par-
ticularly in rare indications, in order to allow timely
access to new treatments. A recent publication has iden-
tified considerable heterogeneity in regulatory and HTA
approaches, even among different European HTA bodies
[10]. Regulatory authorities have adapted their approval
pathways for innovative and promising new medicines
to facilitate early patient access to new treatments, for
example via conditional approval or adaptive pathways
[10]. In order to effectively establish early access to
medicines, HTA procedures need to follow the EMA’s
footsteps and provide harmonised, transparent, flexible,
conditional, and adaptive methods that adopt the level
of evidence accepted by medicines agencies [10].
The UK National Institute for Health and Clinical Ex-
cellence (NICE) uses a less restrictive approach in their
HTA procedure, where appropriate methods may be
used to extrapolate data from less than ideal study de-
signs regarding study type, study duration, patient popu-
lation, choice of comparator, and type of outcomes [19].
In contrast to the approach adopted by the G-BA, where
data that do not fully comply with requirements are
largely rejected, NICE is more receptive to data derived
from clinical trials which are for instance non-
randomised, non-comparative or employ modelling.
Our analysis has revealed that asymptomatic endpoints
were frequently disregarded by the G-BA, while symp-
tomatic endpoints were largely deemed patient-relevant.
However, acceptance of asymptomatic endpoints varied
by therapeutic area. A major achievement in modern
medicine is the ability to capture aspects of morbidity
prior to their transformation in symptomatic disease in
diagnostic and prognostic examinations. For example, in
the assessment of axitinib for renal cell carcinoma, PFS
was used to assess the delay in onset of metastases by
imaging [9]. It is evident that early detection of metasta-
ses before the onset of symptomatic pain or even verte-
bral fractures is essential and of utmost relevance to the
patient. In this case, the strict insistence on symptomatic
endpoints may lead to a delay in complementary treat-
ment options, such as bisphosphonates, which could
prevent occurrence of vertebral fractures [20]. This
would contradict the underlying ethical principles of
diagnosis and therapy in this and many other onco-
logical diseases.
Currently, the G-BA demands patient-relevant out-
come data for the three endpoint categories mortality,
morbidity and HRQoL, and weighs each with equal im-
portance for all assessments. However, a number of rea-
sons may lead to attenuation of mortality data, for
instance, i) clinical advancement of available therapies,
ii) change in disease status from ‘untreatable’ to ‘chronic’,
and iii) differences in the course of diseases themselves.
Given the differences in mortality and progression
between different diseases, for example some forms of
cancer vs non-fatal chronic diseases, equal weighting of
endpoint categories is not informative. Instead, differen-
tial weighting of each endpoint category in the EBA,
taking into account disease type and severity/stage, as
outlined in Fig. 2 would be advisable.
Limitation
For each EBA evaluated, only the respective PEP was in-
cluded, as this is the parameter which provides the most
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clinically relevant and convincing evidence, based on the
statistical principles of clinical trials [21], and clinical tri-
als are explicitly designed to show efficacy in terms of
the PEP. A more comprehensive approach would also
include secondary endpoints. Nevertheless, our approach
sufficiently highlights the clear inconsistencies that exist
between endpoint acceptance by regulatory authorities
and the G-BA.
Conclusions
There is a need for the G-BA to define the morbidity
endpoints that are considered patient-relevant, particularly
in indications such as diabetes and oncological diseases. This
will allow PMs to target clinical trial designs towards re-
quirements of the G-BA at an early clinical development
stage to ensure an efficient pipeline for bringing innovative
and efficacious treatments to patients. In addition, further
harmonisation between regulatory bodies and G-BA with
regards to acceptance of PEPs as relevant to patients is
urgently required. In particular, this applies to morbidity-
related PEPs that are not (yet) symptomatic and tangible to
patients.
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